Cite
HARVARD Citation
Liu, J. et al. (2022). Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology. 40 (19), pp. 2138-2147. [Online].